

BEST AVAILABLE COPY

NOV 16 2005

Page 1 of 1


Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/700.936
	Filing Date	November 4, 2003
	First Named Inventor	Randy S. Bethiel
	Group Art Unit	1624
	Examiner Name	Kahsay Habte
	Attorney Docket Number	VP1/02-123 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
KH	C1	LS Steelman et al., "JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL In Cell Cycle Progression And Leukemogenesis", Leukemia 18: 189-218 (2004)
	C2	Francois-Xavier Mahon, "JAK The Trigger", Oncogene 24: 7125-7126 (2005)
	C3	Stefan Faderl et al., "WP-1034, A Novel JAK-STAT Inhibitor, with Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML)", Anticancer Research 25: 1841-1850 (2005)
	C4	Eliisa A. Sudbeck et al., "Structure-based Design of Specific Inhibitors Of Janus Kinase 3 As Apoptosis-Inducing Antileukemic Agents", Clinical Cancer Research, 5: 1569-1582 (1999)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.